Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: Implications for vaccine design

Cancer Immunology, Immunotherapy

Volumn 57, Issue 9, 2008, Pages 1391-1398

  Kmieciak, Maciej ^a   Morales, Johanna K ^a   Morales, Joshua ^a   Bolesta, Elizabeth ^a   Grimes, Margaret ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Danger signal; HER 2 neu

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MUTANT PROTEIN; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT HEAT SHOCK PROTEIN 110; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER IMMUNOLOGY; CONTROLLED STUDY; DRUG DESIGN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE SYSTEM; INTERFERON TYPE II; LYMPHOCYTES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2;

EID: 45849098275     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0475-8     Document Type: Article

References (35)

1. Banerjee D, Liou HC, Sen R (2005) c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 23:445-458
2. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042-1049
3. Burnet FM (1959) The clonal selection theory of acquired immunity. Vanderbilt University Press, Nashville
4. Burnet FM, Fenner F (1949) The production of antibodies. 2nd edn. Macmillan and Company Limited, Melbourne
5. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF (1999) Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256-3262
6. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546-2553
7. Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114-119
8. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582
9. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL (2004) Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 172:5194-5199
10. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM (2001) Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 167:2602-2607
11. Janeway CA (1992) The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11-16
12. Janeway CA, Medzhitov R (1998) Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 10:349-350
13. Khoruts A, Osness RE, Jenkins MK (2004) IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur J Immunol 34:1085-1090
14. Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675-685
15. Knutson KL, Almand B, Dang Y, Disis ML (2004) Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 64:1146-1151
16. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177:1526-1533
17. Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 558:155-157
18. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G (1993) Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14:203-208
19. Makki A, Weidt G, Blachere NE, Lefrançois L, Srivastava PK (2002) Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun 16;2:4
20. Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL (2006) Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat 96:233-241
21. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR (2003) HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171:4054-4061
22. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301-305
23. Matzinger P (2004) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045
24. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren G (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197-206
25. Méndez R, Ruiz-Cabello F, Rodríguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2007) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother 56:88-94
26. Monzavi-Karbassi B, Artaud C, Jousheghany F, Hennings L, Carcel-Trullols J, Shaaf S, Korourian S, Kieber-Emmons T (2005) Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 174:7057-7065
27. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173:900-909
28. Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164:558-561
29. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188:97-113
30. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177:1272-1281
31. Seong SY, Matzinger P (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4:469-478
32. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, Bell AK, Ferrier RK, Sandilands GP, Gusterson BA (2004) Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 6:R75-91
33. Srivastava PK (2006) Therapeutic cancer vaccines. Curr Opin Immunol 18:201-205
34. Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H (2004) Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res 64:7588-7595
35. Warger T, Hilf N, Rechtsteiner G, Haselmayer P, Carrick DM, Jonuleit H, von Landenberg P, Rammensee HG, Nicchitta CV, Radsak MP, Schild H (2006) Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 281:22545-22553